| The use of viscoelastic haemostatic assays in the management of major bleeding A British Society for Haematology Guideline |
40 |
| Cobomarsen, an oligonucleotide inhibitor of miR- co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma |
39 |
| Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy |
35 |
| Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis |
31 |
| A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma |
30 |
| Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways |
25 |
| Advances in understanding the pathogenesis of acquired aplastic anaemia |
23 |
| The full spectrum of Castleman disease: 273 patients studied over 20 years |
22 |
| Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis |
21 |
| How I manage patients with relapsed/refractory diffuse large B cell lymphoma |
21 |
| Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies |
21 |
| Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome |
20 |
| Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib |
20 |
| Differentiation syndrome in acute promyelocytic leukaemia |
18 |
| Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma |
18 |
| Investigation and management of a raised serum ferritin |
18 |
| Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB |
18 |
| How I manage patients with cold agglutinin disease |
17 |
| British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding |
17 |
| Resistance to proteasome inhibitors and other targeted therapies in myeloma |
17 |
| Advances in targeted therapy for acute myeloid leukaemia |
16 |
| Advances in understanding the pathogenesis of red cell membrane disorders |
15 |
| An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma |
15 |
| Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study |
15 |
| CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib |
15 |
| Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT |
14 |
| A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline |
14 |
| MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survival |
14 |
| Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma |
14 |
| Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations |
13 |
| Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects |
13 |
| Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials |
13 |
| Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach |
13 |
| A tale of two antibodies: obinutuzumab versus rituximab |
13 |
| Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil |
12 |
| A journey through infectious risk associated with ruxolitinib |
12 |
| Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) |
12 |
| von Willebrand factor clearance - biological mechanisms and clinical significance |
12 |
| A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis A British Society for Haematology Guideline |
12 |
| SMAC mimetics as potential cancer therapeutics in myeloid malignancies |
11 |
| A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove |
11 |
| Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations |
11 |
| Citrullinated histone H a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer |
11 |
| Diagnosis of Hodgkin lymphoma in the modern era |
11 |
| Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy |
11 |
| Management of post-transplant lymphoproliferative disorders |
11 |
| Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database |
11 |
| Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions |
11 |
| A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results |
11 |
| CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation |
11 |
